Infection and Drug Resistance (Apr 2022)
Two Cases Report of Intrathecal Tigecycline Therapy for Intracranial Infection with Acinetobacter baumannii and Review of Literatures
Abstract
Guanlin Huang, Wentao Lai, Daxing Wu, Qianliang Huang, Qi Zhong, Xinyun Ye Department of Neurosurgery, Ganzhou People’s Hospital, Ganzhou, Jiangxi, 341000, People’s Republic of ChinaCorrespondence: Xinyun Ye, Department of Neurosurgery, Ganzhou People’s Hospital, Ganzhou, Jiangxi, 341000, People’s Republic of China, Email [email protected]: Objective: To explore the treatment scheme for intracranial infection with Acinetobacter baumannii. Methods: We retrospective analyzed two cases of patients of intracranial infection with Acinetobacter baumannii. Results: The intracranial infection was controlled effectively by the scheme to intravenous“tigecycline + cefperazone-sulbactam”combined with intrathecal tigecycline injection, the two patients recover well with 21 months’ follow-up. Conclusions: Tigecycline-based drug scheme combined with intrathecal tigecycline injection can achieve the effect of controlling intracranial infection. Lumbar cisterna drainage tube plays a major role in controlling intracranial infection.Keywords: multidrug resistant Acinetobacter baumannii, intracranial infection, tigecycline